Sotyktu

Advertisement

cGxPJobs Banner

Bristol Myers Squibb Reports Durable Sotyktu Results in PsA

PRINCETON, N.J. — September 17, 2026 Bristol Myers Squibb announced positive two-year results from the Phase 3 POETYK PsA-2...

By cGxPwire Editor
September 18, 2026

Read More

Bristol Myers Squibb Secures EU Approval for Sotyktu in Psoriatic Arthritis

PRINCETON, N.J., May 11, 2026 Bristol Myers Squibb announced that the European Commission has approved Sotyktu (deucravacitinib) for the...

By cGxPwire Editor
May 12, 2026

Read More

Advertisement

cGxPJobs

Directory